1. Home
  2. Analysis
  3. Oncaspar
  4. Gastroenteritis-norovirus

Oncaspar and Gastroenteritis norovirus - a phase IV clinical study of FDA data

Summary:

Gastroenteritis norovirus is reported as a side effect among people who take Oncaspar (pegaspargase), especially for people who are female, 0-1 old, also take Mercaptopurine, and have Acute lymphocytic leukemia (all).

The phase IV clinical study analyzes which people have Gastroenteritis norovirus when taking Oncaspar. It is created by eHealthMe based on reports of 5,503 people who have side effects when taking Oncaspar from the FDA, and is updated regularly.

What is Oncaspar?

Oncaspar has active ingredients of pegaspargase. eHealthMe is studying from 5,504 Oncaspar users. Check the latest studies of Oncaspar.

What is Gastroenteritis norovirus?

Gastroenteritis norovirus (inflammation of stomach and intestine caused by norovirus infection) is found to be associated with 224 drugs and 345 conditions by eHealthMe. Check the latest studies of Gastroenteritis norovirus.

On Jul, 20, 2026

5,503 people reported to have side effects when taking Oncaspar.
Among them, 32 people (0.58%) have Gastroenteritis norovirus.

Could Oncaspar cause Gastroenteritis norovirus?

Among these 32 people:

What is the gender of people who have Gastroenteritis norovirus when taking Oncaspar? *

  • female: 100 %
  • male: 0.0 %

What is the age of people who have Gastroenteritis norovirus when taking Oncaspar? *

  • 0-1: 72.73 %
  • 2-9: 27.27 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 0.0 %

What are other drugs people take besides Oncaspar? *

  1. Calcium: 13 people, 40.62%
  2. Prednisone: 13 people, 40.62%
  3. Cyclophosphamide: 13 people, 40.62%
  4. Cytarabine: 13 people, 40.62%
  5. Dexamethasone: 13 people, 40.62%
  6. Etoposide: 13 people, 40.62%
  7. Hydrocortisone: 13 people, 40.62%
  8. Mercaptopurine: 13 people, 40.62%
  9. Methotrexate: 12 people, 37.50%
  10. Vincristine Sulfate: 10 people, 31.25%

What are other side effects people have besides Gastroenteritis norovirus? *

  1. Pneumatosis Intestinalis (air or gas in an intestine): 31 people, 96.88%
  2. Clostridium Difficile Colitis (inflammation of colon by clostridium difficile bacteria infection): 31 people, 96.88%
  3. Rhinovirus Infection: 31 people, 96.88%
  4. Bacterial Infection: 30 people, 93.75%
  5. Enteritis (inflammation of the small intestine): 30 people, 93.75%
  6. Human Herpesvirus 6 Infection: 30 people, 93.75%
  7. Viral Infection: 29 people, 90.62%
  8. Venous Thrombosis (blood clot (thrombus) that forms within a vein): 29 people, 90.62%
  9. Secondary Immunodeficiency (lack of immunity due to some disease): 28 people, 87.50%
  10. Enterobacter Infection (infection caused by bacteria of the family enterobacteriaceae): 28 people, 87.50%

What are the existing conditions these people have? *

  1. Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 32 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Oncaspar and have Gastroenteritis norovirus?

- Check whether Gastroenteritis norovirus is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Oncaspar:

Gastroenteritis norovirus treatments and more:

How severe was Gastroenteritis norovirus and when was it recovered:

Expand to all the drugs that have ingredients of pegaspargase:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Oncaspar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gastroenteritis norovirus:

Browse all the conditions that are associated with Gastroenteritis norovirus:

How the study uses the data?

The study uses data from the FDA. It is based on pegaspargase (the active ingredients of Oncaspar) and Oncaspar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.